Historical Perspective on the Introduction and Use of Chemotherapy for the Treatment of Osteosarcoma
Norman Jaffe
Wnt Signaling in Osteosarcoma
Carol H Lin, Tao Ji, Cheng-Fong Chen, Bang H Hoang
Receptor Tyrosine Kinases in Osteosarcoma: Not Just the Usual Suspects
Ashley N. Rettew, Patrick J Getty, and Edward M. Greenberg
Understanding the Role of Notch in Osteosarcoma
Madonna M McManus, Kurt R Weiss, and Dennis PM Hughes
Developmental Pathways Highjacked by Osteosarcoma
Yi Zhang, Jared R Mortus, and Dennis PM Hughes
MicroRNAs in Osteosarcomagenesis
Lisa A Kafchinski and Kevin B Jones
RECQ DNA Helicases and Osteosarcoma
Linchao Lu, Weidong Jin, Hao Liu, and Lisa L Wang
Autophagy in Osteosarcoma
Janice Santiago O'Farrill and Nancy Gordon
HER-2 Involvement in Osteosarcoma
Jonathan Gill, David Geller, and Richard Gorlick
Role of Ezrin in Osteosarcoma Metastasis
Ling Ren and Chand Khanna
Participation of the Fas/FasL Signaling Pathway and the Lung Microenvironment in the Development of Osteosarcoma Lung Metastases
Gangxiong Huang, Kazumasa Nishimoto, Yuanzheng Yang, and Eugenie S Kleinerman
Zebrafish as a Model for Human Osteosarcoma
AB Mohseny and Pancras CW Hogendoorn
Using Canine Osteosarcoma as a Model to Assess Efficacy of Novel Therapies: Can Old Dogs Teach Us New Tricks?
Carlos O Rodriguez
Oncolytic Viruses for Potential Osteosarcoma Therapy
Pooja Hingorani, Valerie Sampson, Christina Lettieri, E. Anders Kolb
IL-11Rα A Novel Target for the Treatment of Osteosarcoma
Valerae Lewis
Bone-seeking Radiopharmaceuticals as Targeted Agents of Osteosarcoma: Samarium-153-EDTMP and Radium-223
Peter M Anderson, Vivek Subbiah, and Eric Rohren
Muramyl Tripeptide-phophatidyl Ethanolamine Encapsulated in Lipomes (L-MTP-PE) in the Treatment of Osteosarcoma
Paul A Meyers
Genetically Modified T-cell Therapy for Osteosarcoma
Christopher DeRenzo and Stephen Gottschalk
Natural Killer Cells for Osteosarcoma
Nidale Tarek, and Dean A Lee.
About the Author: Eugenie S. Kleinerman, M.D. is Professor and Head of the Division of Pediatrics, the first women Division Head at MD Anderson Cancer Center. She is board certified in pediatrics, holds the Mosbacher Pediatrics Chair and is also a Professor of Cancer Biology. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particularly osteosarcoma. She pioneered the use of a unique immunotherapy agent liposome-encapsulated MTP-PE, for children with unresponsive relapsed osteosarcoma lung metastases. Dr. Kleinerman has served on numerous NCI study sections and was a prior member of an FDA advisory panel. She has authored over 177 articles and 21 book chapters and has received over 2900 citations. In 2006, her achievements were recognized by her alma mater, Duke University Medical Center, where she received the Distinguished Medical Alumnus Award. She is the 2009 recipient of the Faculty Achievement Award in Clinical Research.
